Advertisement

Journal of Neuro-Oncology

, Volume 71, Issue 3, pp 295–299 | Cite as

UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma

  • Ulrich HerrlingerEmail author
  • Johannes Rieger
  • Joachim P. Steinbach
  • Thomas Nägele
  • Johannes Dichgans
  • Michael Weller
Clinical Study

Abstract

Glioblastoma is a highly angiogenic tumor with a dismal prognosis. Continuous oral low-dose chemotherapy with methotrexate (MTX) and cyclophosphamide (CPM) has modest activity in heavily pretreated patients with breast cancer. We explored the efficacy of 100 mg CPM daily and 5 mg MTX twice weekly in relapsed glioblastoma. Ten patients, 22–59 years old, with a Karnofsky score of 50% or higher who had failed at least two chemotherapies were accrued. No toxicity was observed. No patient showed a complete or partial response. Five of 10 patients progressed within 2 months of therapy. Another five patients progressed after 3–4.5 months. The median time to progression was 2.5 months. The median overall survival after start of MTX/CPM was 6.9 months (range 0.5–18.8 months). Since the progression-free survival rate at 6 months was 0%, the trial was prematurely closed.

Keywords

antiangiogenic chemotherapy cyclophosphamide glioblastoma low-dose methotrexate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wong, ET, Hess, KR, Gleason, MJ, Jaeckle, KA, Kyritsis, AP, Prados, MD, Levin, VA, Yung, WK 1999Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trialsJ Clin Oncol1725722578Google Scholar
  2. Yung, WK, Albright, RE, Olson, J, Fredericks, R, Fink, K, Prados, MD, Brada, M, Spence, A, Hohl, RJ, Shapiro, W, Glantz, M, Greenberg, H, Selker, RG, Vick, NA, Rampling, R, Friedman, H, Phillips, P, Bruner, J, Yue, N, Osoba, D, Zaknoen, S, Levin, VA 2000A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse.Br J Cancer83588593CrossRefPubMedGoogle Scholar
  3. Fine, HA, Figg, WD, Jaeckle, K, Wen, PY, Kyritsis, AP, Loeffler, JS, Levin, VA, Black, PM, Kaplan, R, Pluda, JM, Yung, WK 2000Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomasJ Clin Oncol18708715Google Scholar
  4. Short, SC, Traish, D, Dowe, A, Hines, F, Gore, M, Brada, M 2001Thalidomide as an anti-angiogenic agent in relapsed gliomasJ Neurooncol514145Google Scholar
  5. Fine, HA, Wen, PY, Maher, EA, Viscosi, E, Batchelor, T, Lakhani, N, Figg, WD, Purow, BW, Borkowf, CB 2003Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomasJ Clin Oncol2122992304Google Scholar
  6. Browder, T, Butterfield, CE, Kraling, BM, Shi, B, Marshall, B, O’Reilly, MS, Folkman, J 2000Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancerCancer Res6018781886PubMedGoogle Scholar
  7. Klement, G, Baruchel, S, Rak, J, Man, S, Clark, K, Hicklin, D, Bohlen, P, Kerbel, RS 2000Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.J Clin Invest105R15R24PubMedGoogle Scholar
  8. Bassukas, ID, Vester, G, Maurer-Schultze, B 1990Cell kinetic studies of endothelial cells in the adenocarcinoma EO 771 and the effect of cyclophosphamideVirchows Arch B Cell Pathol59251256Google Scholar
  9. Hirata, S, Matsubara, T, Saura, R, Tateishi, H, Hirohata, K 1989Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low dose methotrexateArthritis Rheum3210651073Google Scholar
  10. Iwahana, M, Utoguchi, N, Mayumi, T, Goryo, M, Okada, K 1998Drug resistance and P-glycoprotein expression in endothelial cells of newly formed capillaries induced by tumors.Anticancer Res1829772980Google Scholar
  11. Man, S, Bocci, G, Francia, G, Green, SK, Jothy, S, Hanahan, D, Bohlen, P, Hicklin, DJ, Bergers, G, Kerbel, RS 2002Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.Cancer Res6227312735PubMedGoogle Scholar
  12. Miller, KD, Sweeney, CJ, Sledge, GW,Jr. 2001Redefining the target chemotherapeutics as antiangiogenicsJ Clin Oncol1911951206PubMedGoogle Scholar
  13. Gately, S, Kerbel, R 2001Antiangiogenic scheduling of lower dose cancer chemotherapyCancer7427436PubMedGoogle Scholar
  14. Colleoni, M, Rocca, A, Sandri, MT, Zorzino, L, Masci, G, Nole, F, Peruzzotti, G, Robertson, C, Orlando, L, Cinieri, S, De Braud, F, Viale, G, Goldhirsch, A 2002Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levelsAnn Oncol137380Google Scholar
  15. Macdonald, DR, Cascino, TL, Schold, SC,Jr., Cairncross, JG 1990Response criteria for phase II studies of supratentorial malignant gliomaJ Clin Oncol812771280Google Scholar
  16. The Neuro-Oncology Working Group of the German Cancer Society2003Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine pluscytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant gliomaJ Clin Oncol2132763284Google Scholar
  17. Mulne, AF, Ducore, JM, Elterman, RD, Friedman, HS, Krischer, JP, Kun, LE, Shuster, JJ, Kadota, RP 2000Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group studyJ Pediatr Hematol Oncol224144Google Scholar
  18. Hau, P, Baumgart, U, Pfeifer, K, Bock, A, Jauch, T, Dietrich, J, Fabel, K, Grauer, O, Wismeth, C, Klinkhammer-Schalke, M, Allgauer, M, Schuierer, G, Koch, H, Schlaier, J, Ulrich, W, Brawanski, A, Bogdahn, U, Steinbrecher, A 2003Salvage therapy in patients with glioblastoma: is there any benefitCancer9826782686Google Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Ulrich Herrlinger
    • 1
    Email author
  • Johannes Rieger
    • 1
  • Joachim P. Steinbach
    • 1
  • Thomas Nägele
    • 2
  • Johannes Dichgans
    • 1
  • Michael Weller
    • 1
  1. 1.Department of General Neurology, Hertie Institute for Clinical Brain ResearchUniversity of TübingenTübingenGermany
  2. 2.Department of NeuroradiologyUniversity of TübingenTübingenGermany

Personalised recommendations